Form D · Biotechnology
Trethera Corp
Sherman Oaks, CA · CIK 0001639837
Offering snapshot reported May 2, 2025 · SEC filing
- Reported sold
- $250K Offering amount: $5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Apr 29, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 2, 2025 | Initial | $250,000 | No comparison | 1 | SEC filing |
| May 17, 2022 | Initial | $3,833,592 | No comparison | 38 | SEC filing |
| Feb 24, 2021 | Initial | $3,253,368 | No comparison | 25 | SEC filing |
| Apr 17, 2019 | Initial | $580,500 | No comparison | 5 | SEC filing |
| Mar 11, 2019 | Initial | $8,056,505 | No comparison | 28 | SEC filing |
| Mar 7, 2017 | Initial | $4,175,557 | No comparison | 19 | SEC filing |
| Oct 20, 2016 | Amendment | $10,049,743 | $2,649,290vs Feb 23, 2016 | 43 | SEC filing |
| Feb 23, 2016 | Initial | $7,400,453 | No comparison | 40 | SEC filing |
| Jul 2, 2015 | Amendment | $4,854,850 | $4,054,850vs Apr 17, 2015 | 26 | SEC filing |
| Apr 17, 2015 | Initial | $800,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $250K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-545141
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Michael Hughes | 2124662 | Nobles & Richards Inc. · CRD 146870 |
Source: Form D, filed May 2, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Johannes Czernin | Director |
| Jean B. De Kernion | Director, Executive |
| Timothy Donahue, M.D. | Director |
| Laurent Dubois | Director |
| Louis L. Gonda | Director |
| Johanna Holldack | Director, Executive |
| Nathan Mata | Executive |
| Carl Mc Kinzie | Director |
| R. Boyd Quinnell | Director |
| Caius Radu | Director |
| Lynne Rollins | Executive |
| Kenneth A. Schultz, M.D. | Director, Executive |
| John Stretton | Executive |
| Owen Witte, M.D. | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
13547 Ventura Blvd. Suite 363
Sherman Oaks, CA, 91423-3825
Sherman Oaks, CA, 91423-3825